These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 23330947)

  • 1. Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.
    Vauquelin G; Charlton SJ
    Br J Pharmacol; 2013 Apr; 168(8):1771-85. PubMed ID: 23330947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.
    Vauquelin G
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):949-62. PubMed ID: 23812645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands.
    Vauquelin G; Bricca G; Van Liefde I
    Fundam Clin Pharmacol; 2014 Oct; 28(5):530-43. PubMed ID: 24118041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.
    Vauquelin G; Hall D; Charlton SJ
    Br J Pharmacol; 2015 May; 172(9):2300-15. PubMed ID: 25537684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
    Harms BD; Kearns JD; Su SV; Kohli N; Nielsen UB; Schoeberl B
    Methods Enzymol; 2012; 502():67-87. PubMed ID: 22208982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems.
    Vauquelin G; Van Liefde I
    Expert Opin Drug Discov; 2012 Jul; 7(7):583-95. PubMed ID: 22650795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of rigid or flexible linkage between two ligands on the effective affinity and avidity for reversible interactions with bivalent receptors.
    Bobrovnik SA
    J Mol Recognit; 2007; 20(4):253-62. PubMed ID: 17847051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative modeling assesses the contribution of bond strengthening, rebinding and force sharing to the avidity of biomolecule interactions.
    Lo Schiavo V; Robert P; Limozin L; Bongrand P
    PLoS One; 2012; 7(9):e44070. PubMed ID: 23024747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate-binding sites in a single transporter.
    Schmitt KC; Mamidyala S; Biswas S; Dutta AK; Reith ME
    J Neurochem; 2010 Mar; 112(6):1605-18. PubMed ID: 20067583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avidity observed between a bivalent inhibitor and an enzyme monomer with a single active site.
    Lacham-Hartman S; Shmidov Y; Radisky ES; Bitton R; Lukatsky DB; Papo N
    PLoS One; 2021; 16(11):e0249616. PubMed ID: 34847142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays.
    Kaufman EN; Jain RK
    Cancer Res; 1992 Aug; 52(15):4157-67. PubMed ID: 1638531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model and simulation of multivalent binding to fixed ligands.
    Müller KM; Arndt KM; Plückthun A
    Anal Biochem; 1998 Aug; 261(2):149-58. PubMed ID: 9716417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of polyclonal antibody binding of ligand by Sips' equation or by the exact polyclonal equation. Comparison of models.
    Larsson A
    Mol Immunol; 1988 Dec; 25(12):1239-49. PubMed ID: 3237213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo potency revisited - Keep the target in sight.
    Gabrielsson J; Peletier LA; Hjorth S
    Pharmacol Ther; 2018 Apr; 184():177-188. PubMed ID: 29024741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor-Ligand Rebinding Kinetics in Confinement.
    Erbaş A; Olvera de la Cruz M; Marko JF
    Biophys J; 2019 May; 116(9):1609-1624. PubMed ID: 31029377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining the influence of specificity ligands and ATP-competitive ligands on the overall effectiveness of bivalent kinase inhibitors.
    Wong ML; Murphy J; Harrington E; Gower CM; Jain RK; Schirle M; Thomas JR
    Proteome Sci; 2016; 15():17. PubMed ID: 28725163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of the drug-target residence time model.
    Copeland RA
    Expert Opin Drug Discov; 2021 Dec; 16(12):1441-1451. PubMed ID: 34210223
    [No Abstract]   [Full Text] [Related]  

  • 18. Cell-specific targeting by heterobivalent ligands.
    Josan JS; Handl HL; Sankaranarayanan R; Xu L; Lynch RM; Vagner J; Mash EA; Hruby VJ; Gillies RJ
    Bioconjug Chem; 2011 Jul; 22(7):1270-8. PubMed ID: 21639139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of multivalency in the affinity chromatography of antibodies. Appendix: Derivation and evaluation of equations for independent bivalent interacting systems in quantitative affinity chromatography.
    Eilat D; Chaiken IM; McCormick WM
    Biochemistry; 1979 Mar; 18(5):790-5. PubMed ID: 420816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What potential do heterobivalent inhibitors have for the treatment of severe allergic reactions?
    Handlogten MW; Serezani AP; Kaplan MH; Bilgicer B
    Immunotherapy; 2014; 6(3):223-5. PubMed ID: 24762067
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.